Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeTax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Exozymes (EXOZ) EBT (2023 - 2024)

Exozymes (EXOZ) has disclosed EBT for 2 consecutive years, with -$1.8 million as the latest value for Q4 2024.

  • Quarterly EBT fell 74.02% to -$1.8 million in Q4 2024 from the year-ago period, while the trailing twelve-month figure was -$5.9 million through Dec 2024, changed N/A year-over-year, with the annual reading at -$9.3 million for FY2025, 58.05% down from the prior year.
  • EBT for Q4 2024 was -$1.8 million at Exozymes, down from -$1.7 million in the prior quarter.
  • The five-year high for EBT was -$520596.0 in Q3 2023, with the low at -$1.8 million in Q4 2024.